
Interim Safety and Efficacy Results from a Phase 1b Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors
Apr 11, 2022
inPresented at the AACR annual meeting April, 2022
Presented at the AACR annual meeting April, 2022
Presented at the ESMO annual meeting 2021
Presented at the ASCO annual meeting 2020